CKPT Key Statistics, Chart & Performance
The current stock price of CKPT is 4.26 USD. In the past month the price increased by 3.65%. In the past year, price increased by 124.21%.
CKPT Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to CKPT. When comparing the yearly performance of all stocks, CKPT is one of the better performing stocks in the market, outperforming 97.16% of all stocks.
CKPT Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to CKPT. CKPT may be in some trouble as it scores bad on both profitability and health.
CKPT Financial Highlights
Over the last trailing twelve months CKPT reported a non-GAAP Earnings per Share(EPS) of -1.29. The EPS increased by 53.43% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -752.78% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
CKPT Forecast & Estimates
9 analysts have analysed CKPT and the average price target is 4.42 USD. This implies a price increase of 3.76% is expected in the next year compared to the current price of 4.26.
For the next year, analysts expect an EPS growth of 87.52% and a revenue growth 300659% for CKPT
CKPT Ownership
CKPT Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 22.68 | 378.84B | ||
| AMGN | AMGEN INC | 15.11 | 177.92B | ||
| GILD | GILEAD SCIENCES INC | 15.25 | 154.97B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 25.42 | 111.98B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.29 | 77.04B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 704.45 | 47.46B | ||
| INSM | INSMED INC | N/A | 34.43B | ||
| NTRA | NATERA INC | N/A | 31.91B | ||
| BIIB | BIOGEN INC | 9.82 | 24.12B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 23.25B | ||
| INCY | INCYTE CORP | 16.54 | 20.85B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.62 | 20.02B |
Related stock screener links
About CKPT
Company Profile
Checkpoint Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers. The company is headquartered in Waltham, Massachusetts and currently employs 24 full-time employees. The company went IPO on 2016-11-02. The firm is evaluating its lead antibody product candidate, cosibelimab, a potential best-in-class anti-programmed death-ligand 1 (PD-L1) antibody licensed from the Dana-Farber Cancer Institute, as a potential new treatment for patients with selected recurrent or metastatic cancers, including metastatic and locally advanced cutaneous squamous cell carcinoma. The firm is also evaluating its lead small-molecule, targeted anti-cancer agent, olafertinib, a third-generation epidermal growth factor receptor (EGFR) inhibitor, as a potential new treatment for patients with EGFR mutation-positive non-small cell lung cancer. Its anti-GITR monoclonal antibody, CK-302, is a fully human agonistic antibody that is designed to bind to and trigger signaling in GITR expressing cells.
Company Info
CHECKPOINT THERAPEUTICS INC
95 Sawyer Road, Suite 110
Waltham MASSACHUSETTS 10014 US
CEO: James F. Oliviero
Employees: 24
Phone: 17816524500
CHECKPOINT THERAPEUTICS INC / CKPT FAQ
Can you describe the business of CHECKPOINT THERAPEUTICS INC?
Checkpoint Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers. The company is headquartered in Waltham, Massachusetts and currently employs 24 full-time employees. The company went IPO on 2016-11-02. The firm is evaluating its lead antibody product candidate, cosibelimab, a potential best-in-class anti-programmed death-ligand 1 (PD-L1) antibody licensed from the Dana-Farber Cancer Institute, as a potential new treatment for patients with selected recurrent or metastatic cancers, including metastatic and locally advanced cutaneous squamous cell carcinoma. The firm is also evaluating its lead small-molecule, targeted anti-cancer agent, olafertinib, a third-generation epidermal growth factor receptor (EGFR) inhibitor, as a potential new treatment for patients with EGFR mutation-positive non-small cell lung cancer. Its anti-GITR monoclonal antibody, CK-302, is a fully human agonistic antibody that is designed to bind to and trigger signaling in GITR expressing cells.
What is the current price of CKPT stock?
The current stock price of CKPT is 4.26 USD. The price increased by 0.71% in the last trading session.
Does CHECKPOINT THERAPEUTICS INC pay dividends?
CKPT does not pay a dividend.
What is the ChartMill rating of CHECKPOINT THERAPEUTICS INC stock?
CKPT has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
Is CHECKPOINT THERAPEUTICS INC (CKPT) expected to grow?
The Revenue of CHECKPOINT THERAPEUTICS INC (CKPT) is expected to grow by 300659% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
What is the market capitalization of CKPT stock?
CHECKPOINT THERAPEUTICS INC (CKPT) has a market capitalization of 370.71M USD. This makes CKPT a Small Cap stock.
What is the next earnings date for CKPT stock?
CHECKPOINT THERAPEUTICS INC (CKPT) will report earnings on 2025-08-11.